← Evidence map

ArticleMolecular cancer therapeutics2026

Targeting Tumor Microenvironment-Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer.

Brian M Shinder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Targeting Tumor Microenvironment-Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer. | OpenQuestion